Elżbieta Złowocka-Perłowska | kidney cancer | Best Researcher Award

Published on by Research Data Analysis

Dr. Elżbieta Złowocka-Perłowska | kidney cancer | Best Researcher Award

Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University | Poland

PUBLICATION PROFILE

Orcid

Dr. Elżbieta Złowocka-Perłowska⚡🌍

INTRODUCTION 🌟

Dr. Elżbieta Złowocka-Perłowska is a distinguished academic and researcher at the Pomeranian Medical University, specializing in clinical genetics, molecular biology, and hereditary cancers. With over two decades of dedication to the Hereditary Cancer Center at the Department of Genetics and Pathomorphology, she has become an influential figure in medical sciences, particularly focusing on bladder and kidney cancer research. Her work aims to integrate trace element analysis into personalized cancer treatment models, contributing significantly to the field of molecular genetics.

EARLY ACADEMIC PURSUITS 🎓

Dr. Złowocka-Perłowska’s academic journey began with a diploma in Biology from the University of Szczecin in 2002. She then pursued a PhD in Medical Sciences at Pomeranian Medical Academy in Szczecin, where she earned her degree with distinction in 2008. Throughout her early academic years, she demonstrated a deep commitment to the study of genetics and its implications for cancer research.

PROFESSIONAL ENDEAVORS 💼

Since 2002, Dr. Złowocka-Perłowska has been associated with the Hereditary Cancer Center at the Pomeranian Medical University. Her career has evolved from a PhD student to a University Lecturer, Assistant Professor, and National Consultant in Clinical Genetics. She has taught both Polish and English-language courses across various medical and biotechnology programs. Dr. Złowocka-Perłowska’s professional endeavors have led her to direct research projects on cancer diagnostics, utilizing molecular techniques like MLPA, TaqMan, and NGS.

CONTRIBUTIONS AND RESEARCH FOCUS ON kidney cancer🔬

Dr. Złowocka-Perłowska’s research is centered on the study of hereditary cancers, particularly bladder and kidney cancers. Her current research project aims to explore the role of trace elements in cancer prognosis, with a specific focus on blood and serum selenium levels as potential markers for survival. She has conducted extensive studies using molecular genetics techniques and has made significant contributions to the understanding of hereditary cancer genetics. Her scientific work has culminated in 51 publications, four patents (including an international patent), and numerous conference presentations.

IMPACT AND INFLUENCE 🌍

As a recognized leader in the field of hereditary cancer research, Dr. Złowocka-Perłowska has had a profound impact on both medical education and healthcare. Her contributions to clinical studies, research, and the advancement of cancer treatments have been recognized internationally. Through her scientific publications and involvement in research projects, she continues to influence the development of personalized medicine and clinical genetics.

ACADEMIC CITATIONS AND PUBLICATIONS 📚

Dr. Złowocka-Perłowska is the author and co-author of numerous scientific papers published in national and international journals. Her work focuses on hereditary cancers and molecular biology, contributing to the advancement of clinical genetics. With 51 publications to her name, her research is frequently cited by peers in the scientific community. Her papers have been presented at several renowned scientific conferences, establishing her as a thought leader in her field.

HONORS & AWARDS 🏆

Dr. Złowocka-Perłowska has received numerous accolades throughout her career, including the Minister of Health’s Team Award in 2005 and the prestigious “Eminent Scientist of the Year 2009” award from the World Scientist Forum International Awards. She has also been honored with multiple Rector’s Awards for her scientific achievements at Pomeranian Medical University. Other recognitions include certifications for NGS sequencing training and contributions to laboratory medical genetics.

FINAL NOTE ✨

Dr. Złowocka-Perłowska’s work is a testament to the power of academic dedication and scientific inquiry. Her commitment to advancing medical genetics, particularly in the study of hereditary cancers, has significantly shaped the field. Through her research, teaching, and clinical contributions, she continues to inspire future generations of scientists and clinicians.

LEGACY AND FUTURE CONTRIBUTIONS 🔮

Dr. Złowocka-Perłowska’s ongoing research on cancer treatment and prognostic markers positions her as a key figure in the evolution of personalized medicine. With her focus on integrating molecular techniques and trace element analysis, her future contributions will likely continue to revolutionize cancer diagnostics and treatment. She leaves a lasting legacy in the field of medical genetics, with a promising trajectory for further scientific discovery.

TOP NOTES PUBLICATIONS 📚

1. Blood and Serum Copper and Zinc Levels and 10-Year Survival of Patients After Kidney Cancer Diagnosis

  • Authors: Elżbieta Złowocka-Perłowska, Piotr Baszuk, Wojciech Marciniak, Róża Derkacz, Aleksandra Tołoczko-Grabarek, Katarzyna Gołębiewska, Marcin Słojewski, Adam Gołąb, Artur Lemiński, Michał Soczawa, et al.
  • Journal: Nutrients
  • Year: 2025
  • DOI: 10.3390/nu17060944

2. Germline BRCA1 and BRCA2 mutations and the risk of bladder or kidney cancer in Poland

  • Authors: Elżbieta Złowocka-Perłowska, Aleksandra Tołoczko-Grabarek, Steven A. Narod, Jan Lubiński
  • Journal: Hereditary Cancer in Clinical Practice
  • Year: 2022
  • DOI: 10.1186/s13053-022-00220-6

3. Germline HOXB13 mutation p.G84E do not confer an increased bladder or kidney cancer risk in Polish population

  • Authors: Elżbieta Złowocka-Perłowska, Aleksandra Tołoczko-Grabarek, Jan Lubiński
  • Journal: Hereditary Cancer in Clinical Practice
  • Year: 2022
  • DOI: 10.1186/s13053-021-00208-8

4. Recurrent PALB2 mutations and the risk of cancers of bladder or kidney in Polish population

  • Authors: Elżbieta Złowocka-Perłowska, Aleksandra Tołoczko-Grabarek, Jan Lubiński
  • Journal: Hereditary Cancer in Clinical Practice
  • Year: 2021
  • DOI: 10.1186/s13053-020-00161-y

5. Survival of bladder or renal cancer in patients with CHEK2 mutations

  • Authors: Elżbieta Złowocka-Perłowska, Alvaro Galli, Tadeusz Dębniak, Marcin Słojewski, Thierry van de Wetering, Aleksandra Tołoczko-Grabarek, Cezary Cybulski, Rodney J. Scott, Jan Lubiński
  • Journal: PLOS ONE
  • Year: 2021
  • DOI: 10.1371/journal.pone.0257132

 

Matheus Sewastjanow-Silva | Cancer Clinical Trial | Excellence in Research

Published on by Research Data Analysis

Dr. Matheus Sewastjanow-Silva | Cancer Clinical Trial | Excellence in Research

The University of Texas MD Anderson Cancer Center, United States

Author Profiles

Orcid

Scopus

Google Scholar

Early Academic Pursuits 📚

Dr. Matheus Sewastjanow-Silva’s academic journey began at the Federal University of Minas Gerais (UFMG), Brazil, where he completed his Doctor of Medicine (M.D.) degree from 2012 to 2018. During his time at UFMG, he participated in various internships, enhancing his medical expertise across multiple fields, including rural and family medicine, as well as specialized training in dermatology, plastic surgery, and transplant surgery. Additionally, Dr. Sewastjanow-Silva received specialized training at prestigious institutions like A.C. Camargo Cancer Center and Jackson Memorial Hospital, further refining his skills in oncology and surgical specialties.

Professional Endeavors 💼

Dr. Sewastjanow-Silva’s professional career spans various roles at renowned institutions. Currently, he serves as a Research Investigator at the University of Texas MD Anderson Cancer Center (07/2024-present), where he contributes significantly to Shirley Su’s research group in the Department of Head and Neck Surgery. His responsibilities include managing clinical studies/trials databases, manuscript writing, and data analysis, using advanced tools like RedCap, Epic/SlicerDicer, and Prometheus. His prior experience at MD Anderson under Jaffer Ajani’s lab focused on clinical studies and research related to gastrointestinal oncology, where he gained expertise in DNA/RNA extraction, cell culture, and Western Blotting. Additionally, he worked as a physician in several clinics in Brazil, handling outpatient family medicine and emergency care, including COVID-19 patients, displaying his broad clinical knowledge and commitment to patient care.

Contributions and Research Focus 🧬

Dr. Sewastjanow-Silva’s primary research interests lie in oncology, particularly in gastrointestinal cancer and head and neck surgery. Throughout his career, he has been involved in multiple research projects aimed at improving clinical outcomes through the analysis of clinical samples, patient enrollment, and database management. His work involves cutting-edge technologies for analyzing cancer treatment responses, molecular genetics, and experimental models. He has authored and contributed to numerous publications and poster presentations in notable conferences such as the AACR Meeting and ASCO GI, focusing on cancer research and surgical techniques.

Impact and Influence 🌍

Dr. Sewastjanow-Silva has had a significant impact on the field of oncology, particularly through his contributions to clinical research. As a research investigator, he is at the forefront of studying innovative cancer therapies and advancing clinical knowledge in head and neck surgery. He is a respected member of the scientific community, holding memberships in the American Association for Cancer Research (AACR) and the American Society of Clinical Oncology (ASCO). Furthermore, his leadership role in organizing multiple cancer and surgical conferences demonstrates his influence in the academic community, aiming to foster collaboration and drive advancements in cancer research.

Academic Cites 📑

Dr. Sewastjanow-Silva’s academic contributions have garnered recognition within the scientific community, exemplified by his presentations at prominent conferences and his active participation in research publications. His involvement in studies and research protocols has significantly contributed to understanding cancer treatment and surgical outcomes. As a member of the Sigma Xi Scientific Research Honor Society (2024), Dr. Sewastjanow-Silva’s academic citations reflect his growing influence in the field, with numerous abstract and manuscript submissions to journals and conferences.

Technical Skills ⚙️

Dr. Sewastjanow-Silva possesses a robust skill set in both clinical and laboratory settings. His technical expertise includes advanced knowledge in the use of clinical trial management systems like RedCap, Epic/SlicerDicer, and Prometheus. He is proficient in molecular biology techniques such as DNA/RNA extraction, qPCR, Western Blotting, and viral transfections. In addition, he is skilled in cell culture, tissue staining, flow cytometry, and immunohistochemistry. These technical skills allow him to engage in high-level research and clinical analysis, contributing to the progression of cancer therapy.

Teaching Experience 🎓

As a Teaching Assistant at UFMG, Dr. Sewastjanow-Silva mentored first-year medical students, contributing to the academic development of future healthcare professionals. His involvement in various student interest groups, such as those focused on dermatology, anesthesiology, and plastic surgery, highlights his leadership and teaching skills. His role as a coordinator for the Plastic Surgery Student Interest Group further underscores his commitment to fostering the next generation of medical experts.

Leadership and Future Contributions 🌟

Dr. Sewastjanow-Silva’s leadership experience is extensive, having coordinated multiple medical and scientific initiatives at UFMG, such as organizing national campaigns for cancer and burn awareness, as well as medical education activities. As he continues his career at MD Anderson, Dr. Sewastjanow-Silva’s contributions to cancer research and clinical oncology are expected to further elevate his influence. His future endeavors will likely include continuing groundbreaking research, developing novel therapeutic strategies, and further mentoring and educating students and young researchers. His deep commitment to the advancement of medical science and patient care will undoubtedly shape the future of oncology.

Legacy and Lasting Impact 🏆

Dr. Sewastjanow-Silva’s legacy will be defined by his consistent commitment to advancing the field of oncology and his contributions to cancer research and clinical care. Through his extensive work in both Brazil and the United States, he has bridged international research gaps and improved clinical practices. His awards, including the “Young Talent for Science” and honors from Sigma Xi, reflect the significant strides he has made. Looking ahead, Dr. Sewastjanow-Silva will continue to impact the global medical community through innovation, research, and education, shaping the future of cancer care worldwide.

 

📖 Top Noted Publications

Esophageal cancer: emerging therapeutics

Authors: JE Rogers, M Sewastjanow-Silva, RE Waters, JA Ajani

Journal: Expert Opinion on Therapeutic Targets

Year: 2022

Evolution of immune and stromal cell states and ecotypes during gastric adenocarcinoma progression

Authors: R Wang, S Song, J Qin, K Yoshimura, F Peng, Y Chu, Y Li, Y Fan, J Jin, …

Journal: Cancer Cell

Year: 2023

Epithelial SOX9 drives progression and metastases of gastric adenocarcinoma by promoting immunosuppressive tumour microenvironment

Authors: Y Fan, Y Li, X Yao, J Jin, A Scott, B Liu, S Wang, L Huo, Y Wang, R Wang, …

Journal: Gut

Year: 2023

 Challenges and prospects of patient-derived xenografts for cancer research

Authors: J Jin, K Yoshimura, M Sewastjanow-Silva, S Song, JA Ajani

Journal: Cancers

Year: 2023

 Integrated genomic profiling and modelling for risk stratification in patients with advanced oesophagogastric adenocarcinoma

Authors: D Hao, S He, K Harada, MP Pizzi, Y Lu, P Guan, L Chen, R Wang, …

Journal: Gut

Year: 2021

Yang Jiacai | Cancer Research | Best Researcher Award

Published on by Research Data Analysis

Mr. Yang Jiacai | Cancer Research | Best Researcher Award

Institute of Burn Research, State Key Laboratory of Trauma, Burn and Combined Injury, Southwest Hospital, Third Military Medical University, China

 Author Profile 📚

Scopus

Early Academic Pursuits 🎓

Mr. Yang Jiacai began his academic journey with a Master’s degree in Immunology from Shantou University (Guangdong, China) in 2013. His studies initially focused on skin immunology, where he delved into the physiological roles of immune cells such as γδ T cells, macrophages, and fibroblasts in wound healing. His work laid a strong foundation for his later research in skin wound healing mechanisms and the regulation of immune responses during tissue repair.

Professional Endeavors 💼

Currently, Mr. Yang is an experimentalist at the Institute of Burn Research, State Key Laboratory of Trauma, Burn and Combined Injury, Southwest Hospital, Third Military Medical University, Chongqing, China. His research is at the intersection of immunology and wound healing, particularly focusing on the roles of immune cells in skin repair and regeneration. His ongoing projects include a study on scarless wound healing in diabetic wounds and the exploration of DETC functions in burn injuries.

Contributions and Research Focus 🔬

Over the years, Mr. Yang has made significant contributions to the understanding of immune modulation in skin wound healing. His studies on the immune regulatory roles of fibroblast-secreted exosomes and Vγ4+ γδ T cells in macrophage polarization have opened new pathways for potential therapeutic approaches in wound healing. Moreover, his research on the antitumor activity of dendritic epidermal T cells (DETCs) has brought attention to their selective cytotoxicity and potential in cancer immunotherapy.

Impact and Influence 🌍

Mr. Yang’s work has garnered attention in the scientific community, as evidenced by his numerous publications in high-impact journals such as Journal of Investigative Dermatology and iScience. His research has not only contributed to advancing the field of skin wound healing but also provided key insights into immune cell dynamics that could influence cancer immunotherapy. His studies continue to impact both basic research and clinical practices related to burn injuries, wound healing, and tumor immunology.

Academic Cites 📚

Mr. Yang’s research has been widely cited, with several influential papers published in prestigious journals. For instance, his study on the selective cytotoxicity of skin-resident γδ T cells in tumor therapy has recently been published in Journal of Investigative Dermatology (November 2024). Other notable publications include his research on macrophage activation by fibroblast-exosomes in J Invest Dermatol (2025) and on MSCs’ role in angiogenesis in Front Immunol (2022). His work is increasingly recognized for its novel contributions to immunology and wound healing.

Technical Skills 🛠

Mr. Yang is highly skilled in various laboratory techniques related to immunology and skin biology. His expertise includes cellular immunology, flow cytometry, cell culture, wound healing assays, exosome isolation, and molecular biology techniques. Additionally, his proficiency in handling advanced in vitro and in vivo models allows him to investigate the dynamic interactions between immune cells, fibroblasts, and stem cells in skin repair and regeneration.

Teaching Experience 👨‍🏫

Mr. Yang has not listed formal teaching positions, his extensive knowledge and expertise in immunology and wound healing make him a valuable resource for mentorship and training in the lab. His guidance has likely shaped the careers of emerging researchers in the field, and his research collaborations reflect his commitment to knowledge-sharing within the scientific community.

Legacy and Future Contributions 🔮

Mr. Yang’s work has laid the groundwork for future breakthroughs in skin wound healing and cancer immunotherapy. His focus on immune cell dynamics, particularly the roles of γδ T cells and macrophages, promises to transform therapeutic strategies for both burn injuries and tumors. His ongoing research, including scarless wound healing regulation through novel technologies, signals his ongoing contributions to medical innovations. Looking ahead, Mr. Yang’s legacy will continue to inspire future research in immunology and regenerative medicine, with the potential for groundbreaking clinical applications.

 

Top Noted Publications 📖

Orchestration of Macrophage Polarization Dynamics by Fibroblast-Secreted Exosomes during Skin Wound Healing

Authors: Chen, C., Yang, J., Shang, R., Luo, G., He, W.
Journal: Journal of Investigative Dermatology
Year: 2025

Spatiotemporal Orchestration of Macrophage Activation Trajectories by Vγ4 T Cells during Skin Wound Healing

Authors: Hu, W., Zhang, X., Liu, Z., Luo, G., He, W.
Journal: iScience
Year: 2024

Comparison of Inferior Vena Cava Puncture Under Continuous Cardiac Perfusion with Cardiac Puncture in Blood Acquisition of the Laboratory Mouse

Authors: Hu, W., Sheng, H., Yang, J., Huang, C., Luo, G.
Journal: Laboratory Animals
Year: 2024

P311 Promotes IL-4 Receptor‒Mediated M2 Polarization of Macrophages to Enhance Angiogenesis for Efficient Skin Wound Healing

Authors: Chen, C., Tang, Y., Zhu, X., Luo, G., He, W.
Journal: Journal of Investigative Dermatology
Year: 2023

Dendritic Epidermal T Cells Secreting Exosomes Promote the Proliferation of Epidermal Stem Cells to Enhance Wound Re-Epithelialization

Authors: Liu, M., Liu, Z., Chen, Y., Luo, G., He, W.
Journal: Stem Cell Research and Therapy
Year: 2022

Wei Yan | Cancer | Best Faculty Award

Published on by Research Data Analysis

Dr. Wei Yan | Cancer | Best Faculty Award

Wuhan University, China

📚 Author Profile 

Orcid

👩‍🔬 Early Academic Pursuits

Dr. Wei Yan’s academic journey began with a Bachelor of Science in Ocean Biology from the Ocean University of China (2009). This foundational degree set the stage for his profound interest in biological sciences. His pursuit of higher education led him to the Shanghai Institute of Biochemistry and Cell Biology, part of the Chinese Academy of Science, where he obtained his PhD in Biochemistry and RNA Biology (2014). His doctoral research on the mechanisms of leucyl-tRNA synthetase (LeuRS) and its interaction with transfer RNAs (tRNAs) helped elucidate essential catalytic processes, marking the beginning of his contributions to molecular biology.

💼 Professional Endeavors

Following his PhD, Dr. Yan transitioned into postdoctoral research, first at the Beckman Research Institute, City of Hope National Cancer Center, where he delved into the emerging field of extracellular vesicles (EVs), their role in cancer biology, and their potential for cancer diagnosis and treatment. Subsequently, at the University of California, San Diego, he expanded his research on EVs, focusing on their involvement in immune disorders and metabolic diseases. In 2020, Dr. Yan took on the role of Professor at Wuhan University, where he continues to lead innovative research in extracellular vesicle biology and metabolic diseases.

🔬 Contributions and Research Focus on Cancer

Dr. Yan’s early work on LeuRS and its catalytic efficiency provided key insights into the editing domains of tRNA synthetases, contributing to a broader understanding of enzyme specificity and fidelity. His work was instrumental in identifying how these enzymes evolve and adapt, as shown by his Biochemical Journal and Nucleic Acids Research publications in 2012 and 2013.

Currently, Dr. Yan’s research focuses on the biology of extracellular vesicles (EVs), which mediate intercellular communication and have emerged as key players in various diseases, including cancer, obesity, and sepsis. His work examines how stress stimuli influence EV biogenesis, their role in interorgan transportation, and how EVs can be engineered for clinical applications in drug delivery and diagnostics.

🌍 Impact and Influence

Dr. Yan has significantly contributed to the understanding of EV biology and its applications in immune modulation and cancer therapeutics. His studies on the molecular mechanisms of EV cargo transfer provide valuable insights into how cells communicate under both physiological and pathological conditions. Additionally, his work on metabolites’ influence on gene expression in cancer and immune systems is paving the way for new therapeutic strategies.

Dr. Yan’s research has a broad influence on both the basic biology of RNA, enzymes, and extracellular vesicles, as well as their clinical applications. His work continues to gain attention, as evidenced by his invitations to review for leading journals like Cell Metabolism and Journal of Nanobiotechnology, and his editorial roles such as Academic Editor at iScience.

🏆 Honors and Recognition

Dr. Yan’s work has been recognized by the scientific community, earning him prestigious awards such as the 2024 USCACA-AFCR Scholar Award and the 2022 Discover Glo Innovator title from Promega and the Chinese Cell Biology Society. He was also the recipient of the Dependent Care for Postdoc Travel Fellowship in 2018, showcasing the impact of his research both in terms of scientific merit and personal dedication to advancing knowledge.

📚 Academic Cites and Teaching Experience

Dr. Yan has been an active academic mentor and educator since joining Wuhan University as a professor. His courses on biochemistry, RNA biology, and extracellular vesicle biology have influenced a generation of students in molecular biology. His ongoing role as a peer reviewer and editor for various journals further solidifies his position as an academic leader in the field.

Dr. Yan’s publications are widely cited in the field of biochemistry and extracellular vesicles, with his papers in top-tier journals such as Biochemical Journal and Journal of Biological Chemistry being integral to the understanding of protein-RNA interactions and enzyme mechanisms.

🌟 Technical Skills

Dr. Yan is proficient in a wide range of laboratory techniques, including molecular cloning, protein purification, RNA biochemistry, and cell culture. His expertise in extracellular vesicle isolation and characterization allows him to study EV-mediated signaling pathways and develop potential clinical applications for drug delivery and diagnostics. Additionally, he has experience with cutting-edge technologies in mass spectrometry and CRISPR/Cas9 gene editing, enabling his team to explore the functional genomics of EVs in health and disease.

🔮 Legacy and Future Contributions

Dr. Yan’s long-term research goals are focused on revealing the molecular mechanisms of EVs in the context of immune biology and metabolic disorders. His future contributions aim to bridge the gap between basic research and clinical applications, specifically by engineering extracellular vesicles for more efficient drug delivery systems and diagnostic tools. As he continues his research at Wuhan University, his legacy will undoubtedly influence future advancements in extracellular vesicle therapeutics and disease prevention.

 

📖 Top Noted Publications

Extracellular vesicle-mediated interorgan communication in metabolic diseases
    • Authors: Sheng Hu, Yong Hu, Wei Yan
    • Journal: Trends in Endocrinology & Metabolism
    • Year: 2023
Inosine enhances tumor mitochondrial respiration by inducing Rag GTPases and nascent protein synthesis under nutrient starvation
    • Authors: Mei-Xin Li, Xiao-Ting Wu, Wen-Qiang Jing, Wen-Kui Hou, Sheng Hu, Wei Yan
    • Journal: Cell Death & Disease
    • Year: 2023
Cancer-cell-secreted miR-122 suppresses O-GlcNAcylation to promote skeletal muscle proteolysis
    • Authors: Wei Yan, Minghui Cao, Xianhui Ruan, Li Jiang, Sylvia Lee, Adriana Lemanek, Majid Ghassemian, Donald P. Pizzo, Yuhao Wan, Yueqing Qiao, et al.
    • Journal: Nature Cell Biology
    • Year: 2022
Cancer-cell-secreted extracellular vesicles suppress insulin secretion through miR-122 to impair systemic glucose homeostasis and contribute to tumour growth
    • Authors: Cao M, Isaac R, Yan W, Ruan X, Jiang L, Wan Y, Wang J, Wang E, Caron C, Neben S, et al.
    • Journal: Nature Cell Biology
    • Year: 2022
Extracellular Vesicles, New Players in Sepsis and Acute Respiratory Distress Syndrome
    • Authors: Wei Yan
    • Journal: Frontiers in Cellular and Infection Microbiology
    • Year: 2022
Immune Cell-Derived Exosomes in the Cancer-Immunity Cycle
    • Authors: Wei Yan
    • Journal: Trends in Cancer
    • Year: 2020